Combination myeloma therapy almost doubles PFS
Description: Community Oncology Editor Dr. David Henry spoke with Dr. Kenneth Anderson at the Oncology Practice Summit in Las Vegas about the antibody elotuzumab in the treatment of relapsed or refractory multiple myeloma. He notes that as a single agent, the anti-CS humanized monoclonal antibody can achieve stable disease and when used in combination with lenalidomide and low-dose dexamethasone early findings suggest a response rate of 80%-90% and a near doubling of progression-free survival.
The Oncology Practice Summit was the 8th annual meeting of Community Oncology, the journal of clinical issues in community practice. Dr. Henry was a co-chair of the Summit, which was hosted this year by Community Oncology as well as The Journal of Supportive Oncology, and The Oncology Report.
Shared By : feeds
Posted on : 04/22/13
Added : 4 years ago